PSMA Theranostics: Current Status and Future Directions
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metast...
Saved in:
Main Authors: | Kambiz Rahbar MD, Ali Afshar-Oromieh MD, Hossein Jadvar MD, PhD, Hojjat Ahmadzadehfar MD, MSc |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-06-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.1177/1536012118776068 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy
by: Vineet Mohan MSc, et al.
Published: (2020-07-01) -
Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles
by: Heike E. Daldrup-Link MD, PhD
Published: (2017-09-01) -
Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction
by: Courtney Lawhn-Heath MD, et al.
Published: (2018-11-01) -
Radionuclide Imaging for Neuroscience: Current Opinion and Future Directions
by: Antony D. Gee PhD, et al.
Published: (2020-09-01) -
The Patients are Thriving: Further Evidence of Improved Outcomes for Women Surgeons
by: Juliet Emamaullee, MD, PhD, et al.
Published: (2024-12-01)